A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

NCT05676203 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

250

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

DRUG: Standard ADT (androgen deprivation therapy)
DRUG: Standard Darolutamide
DRUG: Docetaxel

Sponsor

Jena University Hospital

Collaborators

[object Object]